Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

2021116 citationsJournal Article

Authors

Enrico Tiacci · Ospedale Santa Maria

Luca De Carolis · Ospedale Santa Maria

Edoardo Simonetti · Ospedale Santa Maria

Monia Capponi · Ospedale Santa Maria

Achille Ambrosetti · University of Verona

Eugenio Lucia · Azienda Ospedaliera di Cosenza

Agostino Antolino ·

Abstract

In this small study, a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with refractory or relapsed HCL. (Funded by the European Research Council and others; HCL-PG03 EudraCT number, 2014-003046-27.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research PI3K/AKT/mTOR signaling in cancer Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 19, pp. 1810-1823

DOI: 10.1056/nejmoa2031298

Field-Weighted Citation Impact: 12.47